by University of Pittsburgh
Certain chemotherapy-resistant ovarian cancer cells protect neighboring cancer cells by sending signals that induce resistance, according to a new study from University of Pittsburgh and UPMC researchers that may help explain why ovarian cancer patients respond … Read more
by NCI Staff
A side effect of some cancer treatments commonly referred to as “chemo brain” has received increasing attention from researchers in recent years. Often referred to as cancer-related cognitive impairment, chemo brain can be marked by severe memory … Read more
CCR scientists have identified dozens of naturally occurring receptors that direct immune cells to tumors with mutations in p53, the most commonly mutated gene in human cancers. The research team, led by Steven Rosenberg, M.D., Ph.D., Chief of the … Read more
by Emily Henderson, B.Sc.
Ovarian cancer has one of the highest death rates of all cancers. One reason for this is that cancer turns the body’s defenses against itself. However, new research from Nagoya University published in Matrix Biology suggests … Read more
Biomedical engineer Daniel Heller leads the Cancer Nanomedicine Laboratory at MSK.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed a sensor that can be trained to sniff for cancer, with the help of artificial intelligence.
Although the training … Read more
by Emily Henderson, B.Sc.
High-grade serous carcinoma is the most aggressive form of ovarian cancer and accounts for the majority of advanced-stage cases. The poor outcomes associated with the disease underscore the need for more effective treatments. A research team … Read more
by Jade Boyd
Rice immunotherapy treatment could begin human clinical trials this year
HOUSTON – (March 2, 2022) – Rice University bioengineers have shown they can eradicate advanced-stage ovarian and colorectal cancer in mice in as little as six days
NEW YORK – A team led by researchers at the University of Helsinki has uncovered stress-related tumor and microenvironment gene expression features that appear to coincide with chemotherapy resistance and shorter progression-free survival in individuals with high-grade serous ovarian cancer.… Read more
Every year, roughly 550 women develop ovarian cancer in Finland. Ovarian cancer is difficult to treat and it is commonly fatal, with 320 women dying of ovarian cancer annually in Finland.
Cancer can only develop and progress when the tumour … Read more
by Emily Dieckman
Jennifer Barton, director of the University of Arizona BIO5 Institute and Thomas R. Brown Distinguished Chair in Biomedical Engineering, has spent years developing a device small enough to image the fallopian tubes. Credit: Chris Richards/University of Arizona… Read more
by Cedars-Sinai
Findings Hold Potential for Predicting Many Years in Advance Which Women With the BRCA-1 Mutation Will Develop Disease
Newswise — Los Angeles (December 28, 2021). –Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S., … Read more
MEDICAL COLLEGE OF WISCONSIN
The study’s findings suggest targeting protein FXR1 to inhibit the progression of the cMYC oncogene, a gene mutation often over-expressed in patients with ovarian cancer
Scientists at the Medical College of Wisconsin (MCW) Cancer Center and … Read more
NOVEMBER 15, 2021, NEW YORK – A Ludwig Cancer Research study has devised a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens—small fragments of randomly mutated proteins that are typically unique to a … Read more
By Asher Jones
Immune checkpoint inhibitors are a type of cancer treatment that help the immune system’s T cells recognize and attack tumors. But these immunotherapy drugs aren’t effective against all cancers. In a study published today in Science Advances… Read more
NOVEMBER 5, 2021, NEW YORK – A Ludwig Cancer Research study has uncovered a cellular interaction that is essential to the ability of the immune system’s cytotoxic T lymphocytes to destroy ovarian tumors and shown that its engagement could help … Read more
by Anne Doerr
New findings by researchers at Yale Cancer Center demonstrate a novel strategy to treat tumor growth in breast and ovarian cancers characterized by HER2 gene amplification, an increase in the number of copies of a gene. Gene … Read more
By Krista Conger
It’s diabolical, and so clever. Recent research by cancer biologist Wendy Fantl, PhD, and immunologist and cancer biologist Veronica Gonzalez, PhD, shows that ovarian tumors thrive by convincing nearby immune cells that the cancer cells are those … Read more
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
The research from UVA’s Jogender Tushir-Singh, PhD, explains why … Read more
All cells use sugar as a vital source of energy and building blocks. Unfortunately, that means even cancer cells use sugar. Researchers at Memorial Sloan Kettering (MSK) Cancer Center wondered what happens when tumor cells and immune cells battle for … Read more
Loss of ARID1A causes increased glutamine metabolism, which can be blocked pharmacologically to target ARID1A-mutant tumors.
Mutations that inactivate the ARID1A gene in ovarian cancer increase utilization of the glutamine amino acid making cancer cells dependent on glutamine metabolism, according … Read more
